Abstracts Archive - Page 971 of 2607 - ACR Meeting Abstracts

Abstract Number: 2019 • ACR Convergence 2020
Preliminary Definition of a Positive MRI for Active Lesions in the Sacroiliac Joints Typical of Axial Spondyloarthritis
Walter Maksymowych¹, Xenofon Baraliakos², Ulrich Weber³, Pedro M Machado⁴, Susanne J Pedersen⁵, Joachim Sieper⁶, Stephanie Wichuk¹, Denis Poddubnyy⁷, Martin Rudwaleit⁸, Désirée van der Heijde⁹, Robert Landewé¹⁰, Joel Paschke¹¹, Mikkel Østergaard¹² and Robert G Lambert¹³, ¹University of Alberta, Edmonton, AB, Canada, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ³University of South Denmark, Odense, Denmark, ⁴University College London, London, United Kingdom, ⁵Rigshospitalet University, Copenhagen, Denmark, ⁶Charité Universitätsmedizin Berlin, Berlin, Germany, ⁷Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁸Department of Internal Medicine and Rheumatology, Klinikum Bielefeld, Germany, ⁹Leiden University Medical Center, Leiden, Netherlands, ¹⁰Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, ¹¹CARE Arthritis, Edmonton, AB, Canada, ¹²Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, ¹³University of Alberta and CARE Arthritis, Edmonton, AB, Canada
Background/Purpose: The ASAS definition of a positive MRI for inflammation (ASAS-MRI+) is intended for classification of patients as having axSpA but is often misused for…
Abstract Number: 2020 • ACR Convergence 2020
Preliminary Definition of a Positive MRI for Structural Lesions in the Sacroiliac Joints in Axial Spondyloarthritis
Walter Maksymowych¹, Xenofon Baraliakos², Ulrich Weber³, Pedro M Machado⁴, Susanne J Pedersen⁵, Joachim Sieper⁶, Stephanie Wichuk¹, Denis Poddubnyy⁷, Martin Rudwaleit⁸, Désirée van der Heijde⁹, Robert Landewé¹⁰, Joel Paschke¹¹, Robert G Lambert¹² and Mikkel Østergaard¹³, ¹University of Alberta, Edmonton, AB, Canada, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ³University of South Denmark, Odense, Denmark, ⁴University College London, London, United Kingdom, ⁵Rigshospitalet University, Copenhagen, Denmark, ⁶Charité Universitätsmedizin Berlin, Berlin, Germany, ⁷Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁸Department of Internal Medicine and Rheumatology, Klinikum Bielefeld, Germany, ⁹Leiden University Medical Center, Leiden, Netherlands, ¹⁰Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, ¹¹CARE Arthritis, Edmonton, AB, Canada, ¹²University of Alberta and CARE Arthritis, Edmonton, AB, Canada, ¹³Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Background/Purpose: There is lack of international consensus as to what defines a structural lesion on MRI of the sacroiliac joints (SIJ) typical of axial spondyloarthritis…
Abstract Number: 2021 • ACR Convergence 2020
The Reliability of Scoring Sonographic Entheseal Abnormalities – the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Lihi Eder¹, Sibel Aydin² and Gurjit Kaeley³, ¹Women’s College Research Institute, University of Toronto, Toronto, ON, Canada, ²University of Ottawa Faculty of Medicine, Rheumatology, Ottawa, ON, CANADA; The Ottawa Hospital Research Institute, Ottawa, ON, CANADA, Ottawa, ON, Canada, ³University of Florida College of Medicine - Jacksonville, Jacksonville, FL
Background/Purpose: DUET is a study supported by the Group for Assessment for Psoriasis and Psoriatic Arthritis (GRAPPA) that aims to develop a novel sonographic scoring…
Abstract Number: 2022 • ACR Convergence 2020
Effects of Anti-TNF-therapy on Osteoblastic Activity in Ankylosing Spondylitis – Results from a Prospective Study Using PET-MRI of SIJ and Spine
Xenofon Baraliakos¹, Styliani Tsiami², Christoph Rischpler³, Nils-Martin Bruckmann⁴, Wolfgang Fendler³, Julian Kirchner⁵, Ken Herrmann³, Lino Morris Sawicki⁵ and Juergen Braun⁶, ¹Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ³Department of Nuclear Medicine, University Essen-Duisburg, Essen, Germany, ⁴Department of Radiology, University Duesseldorf, Düsseldorf, Germany, ⁵Department of Radiology, University Duesseldorf, Duesseldorf, Germany, ⁶Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, 44649 Herne, Germany
Background/Purpose: The clinical efficacy of TNFi in patients with axSpA is well established but its effect on new bone formation is still unclear. Positron emission…
Abstract Number: 2023 • ACR Convergence 2020
Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondylitis: 1-Year Results from a Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension
Atul Deodhar¹, Désirée van der Heijde², Joachim Sieper³, Filip Van den Bosch⁴, Walter Maksymowych⁵, Tae-Hwan Kim⁶, Mitsumasa Kishimoto⁷, Andrew Östör⁸, Bernard Combe⁹, Yunxia Sui¹⁰, Xin Wang¹⁰, Alvina D. Chu¹¹ and In-Ho Song¹⁰, ¹Oregon Health & Science University, Portland, OR, ²Leiden University Medical Center, Leiden, Netherlands, ³Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Ghent University Hospital, Ghent, Belgium, ⁵University of Alberta, Edmonton, AB, Canada, ⁶Hanyang University Hospital for Rheumatic Diseases, Seoul, Seoul-t'ukpyolsi, Republic of Korea, ⁷Department Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ⁸Cabrini Medical Center, Monash University, Malvern, Victoria, Australia, ⁹University of Montpellier, Montpellier, France, ¹⁰AbbVie Inc., North Chicago, IL, ¹¹AbbVie, North Chicago, IL
Background/Purpose: Upadacitinib (UPA), a Janus kinase (JAK) inhibitor, was efficacious and well tolerated vs placebo (PBO) during the first 14 weeks (wks) of the phase…
Abstract Number: 2024 • ACR Convergence 2020
Effects of Filgotinib on Spinal Lesions in Patients with Ankylosing Spondylitis: Magnetic Resonance Imaging Data from the Placebo-Controlled, Double‑Blind, Randomized TORTUGA Trial
Walter Maksymowych¹, Mikkel Østergaard², Robert Landewé³, William Barchuk⁴, Ke Liu⁴, Chantal Tasset⁵, Leen Gilles⁵, Thijs Hendrikx⁶, Robin Besuyen⁶ and Xenofon Baraliakos⁷, ¹University of Alberta, Edmonton, AB, Canada, ²Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, ³Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, ⁴Gilead Sciences, Inc., Foster City, CA, ⁵Galapagos NV, Mechelen, Belgium, ⁶Galapagos BV, Leiden, Netherlands, ⁷Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany
Background/Purpose: The oral, selective Janus kinase 1 inhibitor filgotinib (FIL) significantly improved Spondyloarthritis Research Consortium of Canada (SPARCC) MRI inflammation scores (bone marrow edema) in…
Abstract Number: 2025 • ACR Convergence 2020
Efficacy of Guselkumab, a Monoclonal Antibody That Specifically Binds to the p19 Subunit of IL-23, on Axial-Related Endpoints in Patients with Active PsA with Imaging-Confirmed Sacroiliitis: Week-52 Results from Two Phase 3, Randomized, Double-blind, Placebo-controlled Studies
Philip Mease¹, Philip Helliwell², Dafna Gladman³, Denis Poddubnyy⁴, Xenofon Baraliakos⁵, Soumya Chakravarty⁶, Alexa Kollmeier⁷, Elizabeth Hsia⁸, Xie Xu⁹, Shihong Sheng¹⁰, Prasheen Agarwal¹⁰, Bei Zhou¹⁰, May Shawi¹¹, Chetan Karyekar¹², Kristen Sweet¹⁰, Atul Deodhar¹³ and Désirée van der Heijde¹⁴, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁴Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁵Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ⁶Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ⁷Janssen Research & Development, LLC, La Jolla, CA, ⁸Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, ⁹Janssen Research & Development, LLC, San Marcos, CA, ¹⁰Janssen Research & Development, LLC, Spring House, PA, ¹¹Janssen Global Services, LLC, Toronto, ON, Canada, ¹²Janssen Global Services, LLC, Horsham, PA, ¹³Oregon Health & Science University, Portland, OR, ¹⁴Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Guselkumab (GUS), an interleukin-23 inhibitor, improved axial symptoms of active psoriatic arthritis (PsA) through week 24 in a pooled analysis from two phase 3…
Abstract Number: 2026 • ACR Convergence 2020
Efficacy and Safety of Upadacitinib versus Placebo and Adalimumab in Patients with Active Psoriatic Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Anti-Rheumatic Drugs: A Double-Blind, Randomized Controlled Phase 3 Trial
Iain McInnes¹, Jaclyn K Anderson², Marina Magrey³, Joseph Merola⁴, Yi Liu⁵, Mitsumasa Kishimoto⁶, Slawomir Jeka⁷, Cesar Pacheco Tena⁸, Xin Wang², Liang Chen², Patrick Zueger², Aileen Pangan⁹ and Frank Behrens¹⁰, ¹Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²AbbVie Inc., North Chicago, IL, ³Case Western Reserve University School of Medicine, Cleveland, OH, ⁴Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁵West China Hospital of Sichuan University, Sichuan, China (People's Republic), ⁶Department Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ⁷2nd Univ Hospital, CM UMK, Bydgoszcz, Poland, ⁸Universidad Autonoma de Chihuahua, Chihuahua, Chihuahua, Mexico, ⁹Abbvie Inc., La Grange, IL, ¹⁰CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany
Background/Purpose: Upadacitinib (UPA), an oral, reversible, JAK inhibitor approved to treat rheumatoid arthritis (RA), is under evaluation for psoriatic arthritis (PsA). We assess efficacy and…
Abstract Number: 2027 • ACR Convergence 2020
Efficacy and Safety of Tildrakizumab, a High-Affinity Anti–Interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis in a Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study
Philip Mease¹, Saima Chohan², Ferran J. García Fructuoso³, Alice Gottlieb⁴, Michael Luggen⁵, Proton Rahman⁶, Siba Raychaudhuri⁷, Richard Chou⁸, Alan Mendelsohn⁹, Stephen Rozzo⁹ and Ana-Maria Orbai¹⁰, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Arizona Arthritis and Rheumatology Research, PLLC, Pheonix, AZ, ³Hospital CIMA Sanitas, Barcelona, Spain, ⁴Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, ⁵Cincinnati Rheumatic Disease Study Group, Inc, and Univ of Cincinnati College of Medicine, Cincinnati, OH, ⁶Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ⁷Division of Rheumatology, Allergy & Clinical Immunology, University of California School of Medicine, Davis, and VA Medical Center Sacramento, Sacramento, CA, ⁸Division of Allergy, Immunology and Rheumatology, University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, ⁹Sun Pharmaceutical Industries, Inc., Princeton, NJ, ¹⁰Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Tildrakizumab (TIL), a high-affinity anti–interleukin-23p19 monoclonal antibody, is approved to treat moderate to severe plaque psoriasis.1 The efficacy and safety of TIL up to…
Abstract Number: 2028 • ACR Convergence 2020
Predictors of Maintaining Inactive Disease After Etanercept Withdrawal, and Regaining Inactive Disease Status After Flare and Retreatment, in Adults with Non-radiographic Axial Spondyloarthritis: Results from RE-EMBARK
Filip Van den Bosch¹, James Cheng-Chung Wei², Francisco Blanco³, Pamela Selema⁴, Daniela Graham⁵, Edmund Arthur⁶, Vassilis Tsekouras⁷, Bonnie Vlahos⁴, Chuanbo Zang⁴, Atul Deodhar⁸ and Peter Nash⁹, ¹Ghent University Hospital, Ghent, Belgium, ²Chung Shan Medical University Hospital, Taichung, Taiwan (Republic of China), ³INIBIC-Complejo Hospitalario Universitario A Coruña, A Coruna, Spain, ⁴Pfizer, Collegeville, PA, ⁵Pfizer, Groton, PA, ⁶Pfizer, Peapack, NJ, ⁷Pfizer, Nicosia, Cyprus, ⁸Oregon Health & Science University, Portland, OR, ⁹School of Medicine Griffith University, Brisbane, Queensland, Australia
Background/Purpose: RE-EMBARK was a phase 4, multicenter, open-label, 3-period study that evaluated etanercept (ETN) withdrawal and retreatment in adult patients with non-radiographic axial spondyloarthritis (nr-axSpA)…
Abstract Number: 2029 • ACR Convergence 2020
Therapeutic Drug Monitoring Compared to Standard Treatment of Patients Starting Infliximab: Results from a Multicenter Randomized Controlled Trial of 400 Patients
Silje Syversen¹, Guro Goll¹, Kristin Jørgensen², Øystein Sandanger³, Joseph Sexton¹, Inge C. Olsen³, Johanna Gehin³, Marthe Brun¹, Cato Mørk⁴, Tore K. Kvien¹, Jørgen Jahnsen⁵, Nils Bolstad³ and Espen Haavardsholm¹, ¹Diakonhjemmet Hospital, Oslo, Norway, ²Akershus University Hospital, Oslo, Norway, ³Oslo University Hospital, Oslo, Norway, ⁴Akershus Dermatology Center, Lørenskog, Norway, ⁵Akershus University Hospital, Lørenskog, Norway
Background/Purpose: A lack or loss of response to TNFα inhibitors (TNFi) has been associated with low serum drug levels and formation of anti-drug antibodies (ADAb).…
Abstract Number: 2030 • ACR Convergence 2020
Treatment with Selective Cyclooxygenase-2 Inhibitors Is Associated with Inhibition of Radiographic Spinal Progression in Patients with Axial Spondyloarthritis: Long-term Results from the German Spondyloarthritis Inception Cohort
Denis Poddubnyy¹, Valeria Rios Rodriguez², Murat Torgutalp², Ani Dilbaryan², Maryna Verba², Mikhail Protopopov², Fabian Proft², Judith Rademacher², Hildrun Haibel², Martin Rudwaleit³ and Joachim Sieper², ¹Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Department of Internal Medicine and Rheumatology, Klinikum Bielefeld, Germany
Background/Purpose: There are conflicting data on the effect of non-steroidal anti-inflammatory drugs (NSAIDs) on radiographic spinal progression in axial spondyloarthritis (axSpA). One randomized controlled trial…
Abstract Number: 2031 • ACR Convergence 2020
Which Disease Activity Outcome Measure Discriminates Best in Axial Spondyloarthritis? A Systematic Literature Review and Meta-analysis
Augusta Ortolan¹, Victoria Navarro-Compán², Alexandre Sepriano³, Robert Landewé⁴, Désirée van der Heijde⁵ and Sofia Ramiro⁶, ¹Leiden University Medical Center, Padova, Italy, ²Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, ³Leiden University Medical Center, Portela Loures, Portugal, ⁴Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Several disease activity response and status criteria are used to assess treatment efficacy in RCTs in axial spondyloarthritis (axSpA). Response criteria include: the Assessment…
Abstract Number: 2032 • ACR Convergence 2020
Treatment Response to Biological Disease-modifying Anti-rheumatic Drugs Is Associated with Favorable Changes of the Body Composition in Patients with Ankylosing Spondylitis
Valeria Rios Rodriguez¹, Mikhail Protopopov¹, Fabian Proft¹, Judith Rademacher¹, Burkhard Muche¹, Anne-Katrin Weber¹, Susanne Lüders¹, Hildrun Haibel¹, Maryna Verba¹, Joachim Sieper¹ and Denis Poddubnyy², ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: There is few data available regarding differences in body composition and its possible changes in patients with ankylosing spondylitis (AS) treated with biological disease-modifying…
Abstract Number: 2033 • ACR Convergence 2020
Large-scale Examination of Longitudinal Skin Gene Expression and Its Associations with Skin Thickness in Systemic Sclerosis
Brian Skaug¹, Marka Lyons¹, William Swindell², Gloria Salazar¹, Julio Charles¹, Connor Vershel¹, Maureen Mayes³ and Shervin Assassi³, ¹University of Texas Houston, McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ²The Jewish Hospital, Department of Internal Medicine, Cincinnati, OH, ³University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX
Background/Purpose: Numerous studies have revealed dysregulated gene expression in the skin of systemic sclerosis (SSc) patients, with varying degrees of inflammatory/immune and fibroblast upregulation. However,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].